Updated Jul 16, 2026
Young Jonathan is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $5.28M.
Jonathan Young is the Chief Operating Officer at Akero Therapeutics, Inc., a biotechnology company focused on developing treatments for liver diseases. He has been involved in multiple SEC filings related to his role at the company.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2025-12-09 | AKRO | Akero Therapeutics, Inc. | D — Derivative transaction | 47.6K | — | |
| 2025-12-09 | AKRO | Akero Therapeutics, Inc. | D — Derivative transaction | 20.0K | — | |
| 2025-12-09 | AKRO | Akero Therapeutics, Inc. | D — Derivative transaction | 20.0K | — | |
| 2025-12-09 | AKRO | Akero Therapeutics, Inc. | D — Derivative transaction | 20.0K | — | |
| 2025-12-09 | AKRO | Akero Therapeutics, Inc. | D — Derivative transaction | 152.6K | — | |
| 2025-11-26 | AKRO | Akero Therapeutics, Inc. | G — Bona-fide gift | 9.3K | $0.00 | |
| 2025-11-26 | AKRO | Akero Therapeutics, Inc. | M — Option exercise | 4.7K | $21.10 | $100K |
| 2025-11-26 | AKRO | Akero Therapeutics, Inc. | M — Option exercise | 3.5K | $28.35 | $100K |
| 2025-11-26 | AKRO | Akero Therapeutics, Inc. | M — Option exercise | 4.3K | $21.09 | $90K |
| 2025-10-01 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 4.2K | $47.98 | $202K |
| 2025-10-01 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 8.3K | $47.64 | $395K |
| 2025-10-01 | AKRO | Akero Therapeutics, Inc. | M — Option exercise | 12.5K | $21.10 | $264K |
| 2025-09-11 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 586 | $43.02 | $25K |
| 2025-09-02 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 61 | $47.58 | $3K |
| 2025-09-02 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 2.7K | $47.14 | $129K |
| 2025-09-02 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 9.7K | $45.78 | $444K |
| 2025-09-02 | AKRO | Akero Therapeutics, Inc. | M — Option exercise | 12.5K | $21.10 | $264K |
| 2025-08-12 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 1.3K | $48.32 | $65K |
| 2025-08-12 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 11.2K | $47.72 | $532K |
| 2025-08-12 | AKRO | Akero Therapeutics, Inc. | M — Option exercise | 12.5K | $21.10 | $264K |
Jonathan Young is the Chief Operating Officer at Akero Therapeutics, Inc., a biotechnology company focused on developing treatments for liver diseases. He has been involved in multiple SEC filings related to his role at the company.…
Recorded transactions: 0 open-market purchases () and 15 open-market sales ($5.28M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Young Jonathan profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.